Trial Profile

A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYAD 01 (Primary)
Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Sponsors Celdara Medical; Celyad Oncology

Most Recent Events

30 May 2018 Status changed from active, no longer recruiting to completed.
06 Dec 2016 Results of phase I portion of this study (n=11) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
07 Nov 2016 According to Celyad media release, results which will be presented during a poster session at the 58th American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com